Foresight has developed a new platform for MRD detection that decreases the LOD to tumor burden levels as low as 0.5 ppm, potentially eliminating treatment blind spots by enabling continuous MRD ...

Their blood samples were evaluated for circulating tumor DNA (ctDNA) using both ddPCR-based and Veracyte’s WGS-based MRD testing platform to detect disease recurrence. Patients also underwent ...